Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

141. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomiz (Full text)

Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomiz To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TAT) in patients with atrial fibrillation (AF) and acute coronary syndrome or who underwent percutaneous coronary intervention (PCI).A systematic (...) review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials comparing DAT vs. TAT in AF patients undergoing PCI. Four trials encompassing 10 234 patients (DAT = 5496 vs. TAT = 4738) were included. The primary safety endpoint (ISTH major or clinically relevant non-major bleeding) was significantly lower with DAT compared with TAT [risk ratio (RR) 0.66, 95% confidence interval (CI) 0.56-0.78; P < 0.0001; I2 = 69

2020 European Heart Journal PubMed abstract

142. Prognostic value of office blood pressure measurement in patients with atrial fibrillation on anticoagulation therapy: systematic review and meta-analysis. (Abstract)

Prognostic value of office blood pressure measurement in patients with atrial fibrillation on anticoagulation therapy: systematic review and meta-analysis. In patients with atrial fibrillation (AF), the clinical relevance of office blood pressure (OBP) measurement in terms of predicting morbidity and mortality is questionable, mainly because such measurements in these patients are variable and uncertain. This study reviewed the evidence on the prognostic value of OBP in AF.A systematic PubMed (...) /Embase search was performed for prospective trials in AF patients on oral anticoagulants, reporting OBP measurements or hypertension diagnosis and outcome. A meta-analysis of the predictive ability of OBP values or hypertension diagnosis for stroke/systemic embolism, major haemorrhage and all-cause mortality was performed.The meta-analysis included nine studies (n = 65 637; 126 926 person-years). There was considerable heterogeneity in the OBP methodology, which was not standardized in most studies

2020 Journal of Hypertension

143. Consequences of pre-injury utilization of direct oral anticoagulants in patients with traumatic brain injury: A systematic review and meta-analysis. (Abstract)

Consequences of pre-injury utilization of direct oral anticoagulants in patients with traumatic brain injury: A systematic review and meta-analysis. The rapid adoption and widespread use of direct oral anticoagulants (DOACs) has outpaced research efforts to establish their effects in bleeding trauma patients. In patients with complicated traumatic brain injury (TBI) caused by intracranial hemorrhage, DOAC use may be associated with higher bleeding volume and potentially more disastrous sequelae (...) ," "direct oral anticoagulants," and "vitamin K antagonists." There were 1,446 abstracts screened, and ultimately, six included articles. Random effects modeling meta-analysis was performed on in-hospital mortality, ICH progression and neurosurgical intervention rate.All cohorts had similar baseline and emergency department parameters. Within individual studies surgery rate, reversal agents used, ICH progression and in-hospital mortality differed significantly between DOAC and VKA cohorts. Meta-analysis

2020 The journal of trauma and acute care surgery

144. Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation: A meta-analysis. (Full text)

Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation: A meta-analysis. The role of anticoagulation therapy for stroke prevention in older atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unclear. Therefore, we conducted a meta-analysis to explore the efficacy and safety of anticoagulation therapy in this population.The Cochrane Library, PubMed, and Embase databases were systematically searched for studies reporting (...) the effect of anticoagulation therapy in older patients with AF and CKD. The risk ratios (RRs) and 95% confidence intervals (CIs) were regarded as the risk estimates. A random-effects model selected was to evaluate the treatment outcomes. The presentations were based on the Preferred Reporting Items for reporting systematic reviews and meta-analyses statement.A total of 7 studies with 24,794 older patients with AF and CKD were included. The follow-up of the included studies ranged from 0.9 to 9.0 years

2020 Medicine PubMed abstract

145. World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta-analysis. (Full text)

World workshop on oral medicine VII: Direct anticoagulant agents management for invasive oral procedures: A systematic review and meta-analysis. This systematic review aimed to evaluate the current literature regarding the importance of discontinuing or not discontinuing direct oral anticoagulants (DOACs) before invasive oral procedures, and to establish the frequency and type of postoperative bleeding events in patients.We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane

2020 Oral diseases PubMed abstract

146. Kidney Pre-biopsy medication: Antiplatelet and anticoagulant agents

Kidney Pre-biopsy medication: Antiplatelet and anticoagulant agents ____________________________________________________________________________________________________________ Renal Biopsy - Desmopressin Acetate July 2018 Page 1 of 15 2. PRE – BIOPSY MEDICATION – ANTIPLATELET AND ANTICOAGULANT AGENTS Date written: March 2018 Authors: Emily See, Paul Champion de Crespigny, Pamela Lopez-Vargas, Talia Gutman, Karine Manera, Solomon Menahem, John Saunders, David Voss, Jeffrey Wong and Rob (...) (to prevent major bleeding) or 7 days (to prevent minor bleeding) prior to the renal biopsy (1C). c. We suggest the use of bridging anticoagulation in patients at highest risk for thromboembolism. This includes patients with a mechanical mitral valve, a mechanical aortic valve and additional stroke risk factors, antiphospholipid syndrome, an embolic event within the previous 3 months, atrial fibrillation (CHADS2 score 5 or 6), and a previous thromboembolic event with interruption of anticoagulation (2C

2020 KHA-CARI Guidelines

147. What is the appropriate anticoagulation for patients with antiphospholipid syndrome?

What is the appropriate anticoagulation for patients with antiphospholipid syndrome? Chiefs’ Inquiry Corner – 1/6/19 – Clinical Correlations Search Chiefs’ Inquiry Corner – 1/6/19 January 6, 2020 2 min read Direct oral anticoagulants (DOACs) have replaced warfarin for many indications because they are effective and easier to use. Antiphospholipid syndrome is a notable exception to this trend. In a trial of 120 high risk patients with antiphospholipid syndrome randomized to rivaroxaban versus

2020 Clinical Correlations

148. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. (Abstract)

Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. Elderly population is known to be associated with polymedication, comorbidities and altered drug pharmacokinetics. However, the most adequate oral anticoagulant, attending to its relative efficacy and safety, remains unclear.We searched for phase III randomized controlled trials (MEDLINE, Cochrane Library, SciELO collection and Web (...) of Science) comparing novel non-vitamin K antagonist oral anticoagulants (NOACs) with Vitamin K antagonists (VKA) in the elderly population (≥75 years-old) in atrial fibrillation (AF). Risk ratios (RR) were calculated using a random effects model. Trial sequential analysis (TSA) was performed in statistically significant results to evaluate whether cumulative sample size was powered.Four trials rendered data about elderly (≥75 years-old) and younger patients (<75 years-old) with AF. NOACs demonstrated

2019 Archives of gerontology and geriatrics

149. Evaluation of therapeutic efficacy of anticoagulant drugs for patients with venous thromboembolism during pregnancy: A systematic review and meta-analysis. (Abstract)

Evaluation of therapeutic efficacy of anticoagulant drugs for patients with venous thromboembolism during pregnancy: A systematic review and meta-analysis. A meta-analysis based on published literature was undertaken to evaluate the efficacy of anticoagulant drugs for the treatment of venous thromboembolism during pregnancy. PubMed, Cochrane and Embase databases were searched from inception to September 2018 for relevant studies using indexed words, including qualified case-control and cohort (...) was significantly higher in the case group than in the control group (OR 3.90, 95% CI 1.23-12.34). However, there were a few limitations that may have influenced the results, so more randomized double-blind controlled studies of high quality are warranted to confirm the efficacy of anticoagulant therapy for venous thromboembolism in pregnancy.Copyright © 2019 Elsevier B.V. All rights reserved.

2019 European journal of obstetrics, gynecology, and reproductive biology

150. Anticoagulation in Patients Prone to Falling. (Abstract)

Anticoagulation in Patients Prone to Falling. 31299015 2019 12 20 2019 12 20 1536-3686 26 4 2019 Jul/Aug American journal of therapeutics Am J Ther Anticoagulation in Patients Prone to Falling. e495-e498 10.1097/MJT.0000000000000712 Stupey Jennifer E JE Northern Arizona VA Health Care System, Prescott, AZ. Mellen Chadwick K CK Rindone Joseph P JP eng Editorial Meta-Analysis United States Am J Ther 9441347 1075-2765 0 Anticoagulants 5Q7ZVV76EI Warfarin IM Accidental Falls statistics & numerical (...) data Administration, Oral Age Factors Aged Aged, 80 and over Anticoagulants administration & dosage adverse effects Clinical Trials as Topic Hospital Mortality Hospitalization statistics & numerical data Humans Intracranial Hemorrhages etiology mortality therapy Warfarin administration & dosage adverse effects 2019 7 13 6 0 2019 7 13 6 0 2019 12 21 6 0 ppublish 31299015 10.1097/MJT.0000000000000712 00045391-201908000-00010

2019 American journal of therapeutics

151. Erratum to 'A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients With Cancer' [European Journal of Vascular & Endovascular Surgery 57/5 (2019) 685-701]. (Full text)

Erratum to 'A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients With Cancer' [European Journal of Vascular & Endovascular Surgery 57/5 (2019) 685-701]. 31594697 2019 12 18 1532-2165 58 6 2019 Dec European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery Eur J Vasc Endovasc Surg Erratum to 'A Systematic Review and Meta-Analysis of the Efficacy (...) and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients With Cancer' [European Journal of Vascular & Endovascular Surgery 57/5 (2019) 685-701]. 943 S1078-5884(19)32018-0 10.1016/j.ejvs.2019.09.505 Kirkilesis George I GI Department of Vascular Surgery, University Hospital of Patras, Patras, Greece. Kakkos Stavros K SK Department of Vascular Surgery, University Hospital of Patras, Patras, Greece. Electronic address: kakkos@upatras.gr. Tsolakis Ioannis A IA Department

2019 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery PubMed abstract

152. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. (Abstract)

Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) including the comparison of non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin for patients with atrial fibrillation (AF).Network meta-analysis. Two authors independently extracted data. All authors evaluated overall confidence in the evidence.Eighteen RCTs included in our review, a total

2019 Scandinavian cardiovascular journal : SCJ

153. Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis. (Full text)

Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis. We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC) treatment. A search of the medical literature was performed from inception until May 31, 2019. Inclusion criteria were (1) randomized trial that assessed the clinical efficacy and/or safety of 1 or more DOAC, (2) control group including oral anticoagulation and/or antiplatelet and/or placebo treatment (...) -0.89]) when compared to dabigatran. Apixaban resulted in 24% (RR: 0.76 [95% CrI: 0.58-0.99]) and vitamin K antagonists anticoagulation resulted in 19% (RR: 0.81 [95% CrI: 0.65-0.98]) risk reduction compared to dabigatran. The computed probability of being the first best choice of treatment was 61.8% for rivaroxaban. Cardiovascular safety shows considerable heterogeneity among oral anticoagulants. Treatment with rivaroxaban is associated with reduced rate of MI.

2019 Angiology PubMed abstract

154. Correction to: Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta-analysis. (Full text)

Correction to: Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta-analysis. The article Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta‑analysis, written by Xin Cao, Jun Zhang and Daoying Geng, was originally published electronically on the publisher's internet portal (currently SpringerLink) on April 2019 with open access. With the author(s)' decision to step

2019 Journal of thrombosis and thrombolysis PubMed abstract

155. Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. (Full text)

Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. 30309478 2019 09 10 2019 12 10 1558-3597 72 16 2018 10 16 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. 1984-1986 S0735-1097(18)36958-4 10.1016/j.jacc.2018.07.083 Kotecha Dipak D Pollack Charles V CV Jr De Caterina Raffaele R Renda Giulia G Kirchhof Paulus P eng CDF (...) -2015-08-074 Department of Health United Kingdom Letter Meta-Analysis Research Support, Non-U.S. Gov't United States J Am Coll Cardiol 8301365 0735-1097 0 Anticoagulants 0 Antithrombins 5Q7ZVV76EI Warfarin AIM IM Anticoagulants therapeutic use Antithrombins classification therapeutic use Atrial Fibrillation complications therapy Electric Countershock adverse effects methods Humans Outcome and Process Assessment, Health Care Thromboembolism diagnosis etiology Warfarin therapeutic use 2018 04 13 2018

2019 Journal of the American College of Cardiology PubMed abstract

156. Is Anticoagulant Necessary in Patients with Coronary Artery Ectasia Presenting with Acute Coronary Syndrome? A Systematic Review of Case Reports. (Abstract)

Is Anticoagulant Necessary in Patients with Coronary Artery Ectasia Presenting with Acute Coronary Syndrome? A Systematic Review of Case Reports. Coronary artery ectasia is found in 3 to 8% of patient's undergoing angiography and may sometimes induce acute myocardial infarction. Some articles reported a recurrence of acute coronary syndrome (ACS) in the presence of coronary artery ectasia (CAE). Our study aims to summarize the latest evidence on whether the use of anticoagulant in addition (...) to SAPT/DAPT (single antiplatelet/dual antiplatelet) treating ACS with CAE patients is necessary. Since the trials concerning our objectives were scarce, we pooled case reports/series. We performed a comprehensive search on case reports/series on coronary artery ectasia that presented with acute coronary syndrome published until March 2019. We collected 13 cases from 11 reports. Out of 13 patients, 5 (38.5%) took DAPT only without anticoagulant and 8 (61.5%) took anticoagulant ± DAPT. Three out

2019 The International journal of angiology : official publication of the International College of Angiology, Inc

157. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. (Abstract)

Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. Several studies have explored the use of NOACs compared with vitamin K antagonists (VKAs) in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF); and therefore, we aimed to compare the efficacy and safety outcomes of NOACs with VKAs in this population. We systematically searched the PubMed and Embase databases until

2019 Journal of thrombosis and thrombolysis

158. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation (Abstract)

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation Warfarin is prescribed to patients with atrial fibrillation (AF) for the prevention of cardioembolic complications. Whether warfarin adversely affects bone health is controversial. The availability of alternate direct oral anticoagulant (DOAC) options now make it possible to evaluate the comparative safety of warfarin in association with fracture risk.To test the hypothesis that, among patients (...) with nonvalvular AF, use of DOACs vs warfarin is associated with lower risk of incident fracture.This comparative effectiveness cohort study used the MarketScan administrative claims databases to identify patients with nonvalvular AF and who were prescribed oral anticoagulants from January 1, 2010, through September 30, 2015. To reduce confounding, patients were matched on age, sex, CHA2DS2-VASc (congestive heart failure, hypertension, age [>65 years = 1 point; >75 years = 2 points], diabetes, and previous

2019 EvidenceUpdates

159. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants (Abstract)

Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures.The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA (...) or direct oral anticoagulants (DOACs).Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint.Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI

2019 EvidenceUpdates

160. Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency. (Abstract)

Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency. The management of anticoagulant therapy (OAT) in patients with factor VII (FVII) deficiency is a very challenging clinical issue, as warfarin further reduces FVII levels, thus potentially increasing bleeding risk. On the other hand, the International Normalized Ratio test is misleading in such patients, as they do not reflect the actual level of global inhibition of the coagulation system. We (...) report here three cases of patients with a moderate FVII deficiency and receiving direct oral anticoagulants (DOAC) for prevention of cardioembolism in atrial fibrillation. Of note, two of them experienced a treatment failure while on warfarin, while DOAC treatment was not associated with thrombotic or hemorrhagic adverse events. DOAC are very attractive for the management of OAT in FVII deficient patients, because they do not require monitoring by tests affected by the inherited defect

2019 European journal of haematology